(Total Views: 582)
Posted On: 10/08/2020 10:59:51 AM
Post# of 154119
Re: Lee Ron Lemab #60410
There is no doubt going to be competition in the near future for therapeutics.
The question is: will the therapeutics show efficacy in the severe/critical population? Regeneron or Eli Lily’s drug may reduce the number of patients who progress to the severe/critical category but there will still be patients who don’t respond to these medications and progress to the ICU and mechanical ventilation. That’s hopefully where leronlimab fits into the therapeutic equation for COVID19, although I think there’s a reason to argue that leronlimab May also prevent progression to the severe/critical category based on the NEWS2 data from the M2M trial.
The question is: will the therapeutics show efficacy in the severe/critical population? Regeneron or Eli Lily’s drug may reduce the number of patients who progress to the severe/critical category but there will still be patients who don’t respond to these medications and progress to the ICU and mechanical ventilation. That’s hopefully where leronlimab fits into the therapeutic equation for COVID19, although I think there’s a reason to argue that leronlimab May also prevent progression to the severe/critical category based on the NEWS2 data from the M2M trial.
(3)
(0)
